Introduction
Immunophenotypic analysis of the reactivity of leukaemic cells with monoclonal antibodies has proved useful and nowadays essential in the diagnosis of acute leukaemias. This was first shown to be relevant in the characterisation and classification of acute lymphoblastic leukaemias of various cell types12 as there is no specific and reliable cytochemical marker to recognise lymphoblasts. Subsequently, immunological markers have also been shown to be important in the diagnosis of acute myeloblastic leukaemias, particularly when the nature of the blasts cannot be defined by morphology and cytochemistry. Examples of these "undifferentiated" acute leukaemias include those with poorly differentiated myeloblasts (AML-M0),>5 or those derived from early erythroid and megakaryocyte precursors.6 There is currently a large panel of monoclonal antibodies (over 1000) available which detect different molecules (over 70) on normal haemopoietic and leukaemic cells of various lineages. These monoclonal antibodies are grouped according to the molecule or antigen that they recognise under a cluster designation or differentiation (CD) number which extends from 1 to 76. Only a minority of these reagents have been shown to be helpful for the diagnosis of acute leukaemia: these comprise monoclonal antibodies which recognise antigens in lymphoid/myeloid cells from the earlier stages of differentiation and which, with few exceptions, are cell lineage restricted. In this review an outline will be given of: (i) The same procedure is applied for flow cytometry analysis, but following the incubation with the FITC anti-mouse immunoglobulin and subsequent washes, the cell pellet is resuspended in 500 ,ul of Isoton and assessed on the flow cytometer. If the sample is to be analysed more than four hours after staining, the cell pellet should be fixed in 1% paraformaldehyde in 0-85% saline instead of being resuspended in Isoton.
Whole blood can be also tested by flow cytometry without the need for isolation of the mononuclear fraction according to the manufacturer's instructions. Usually, 100-200 ,ul of blood are incubated with the monoclonal antibody, followed by the addition of FITC conjugated antimouse immunoglobulin. The methodology is identical to that described above but the buffer used does not contain human serum and the pellet, following the immunostaining, is treated with 1 ml of lysing solution for 10 minutes at room temperature and washed twice in buffer (PBSazide). Finally, the cell pellet is resuspended in 250 ,ul of Isoton and the measurement is performed in the flow cytometer.
In some circumstances, for instance in biphenotypic/mixed lineage acute leukaemias, or for the detection of minimal residual disease, it may be useful to apply a double labelling technique to determine whether a single cell population coexpresses two different antigens in the membrane. Usually, a direct immunofluorescence technique using two directly conjugated monoclonal antibod-ies to two fluorochromes (such as fluorescein and phycoerythrin) is applied. The monoclonal antibodies should be independently titrated and the methodology is similar to that of the indirect immunofluorescence described above with the omission of the second incubation step.
Negative control preparations should be set up In the remaining cases of acute leukaemia in which the blasts are shown to be myeloid by standard light microscopy, morphology, and cytochemistry (such as presence of Auer rods or myeloperoxidase activity), the immunological markers are not essential as in the group outlined above. Still, it is recommended that the immunological profile of these blast cells be investigated to rule out cases of biphenotypic/mixed lineage acute leukaemia9 10 in which the blasts have myeloid and lymphoid features despite presenting as AMIL.9 10 Immunological markers are not useful in cases of chronic myeloproliferative disorders and myelodysplasia with no evidence of blast transformation. 1 Greaves MF, Janossy J, Peto J, Kay H. Immunologically
